Tyme Technologies Inc represents a commitment to innovation, patient-centricity, and scientific rigor. With a focus on advancing breakthrough cancer treatments, the company's corporate philosophy emphasizes the importance of delivering safe and effective therapies that improve patients' lives. Tyme Technologies Inc is dedicated to conducting rigorous research and clinical studies that advance the understanding and treatment of various forms of cancer. Their mission is to revolutionize cancer care by developing novel therapies that target the metabolic and genetic pathways unique to cancer cells. Through their cutting-edge approach, Tyme Technologies Inc strives to bring hope and new treatment options to cancer patients worldwide.

Tyme Technologies Inc is primarily present in the United States.

Tyme Technologies Inc has achieved several significant milestones. One of the major milestones for the company was obtaining orphan drug designation from the U.S. FDA for its lead product candidate, SM-88. Tyme also successfully completed a Phase II trial for SM-88 in patients with metastatic pancreatic cancer. Furthermore, the company has expanded its clinical pipeline by initiating Phase II trials for SM-88 in additional types of cancer, including prostate and breast cancer. Tyme Technologies Inc has demonstrated promising progress in advancing its innovative therapies and is poised for further growth and development.

Tyme Technologies Inc is a pharmaceutical company focused on developing innovative cancer treatments. Founded in 2011, the company is headquartered in New York, USA. Tyme Technologies is committed to improving the lives of cancer patients through its proprietary research and development activities. The company focuses on the development of cancer metabolism-based therapies that have the potential to overcome drug resistance, reduce side effects, and provide more effective treatment options. Tyme Technologies is dedicated to advancing its pipeline of novel therapies, with a particular focus on metastatic cancers.

The main competitors of Tyme Technologies Inc in the market are pharmaceutical companies that focus on developing and marketing cancer treatments. These competitors include well-established companies such as Roche Holdings AG, Pfizer Inc, and Merck & Co. Tyme Technologies Inc faces competition in the development and commercialization of its lead candidate, SM-88, which aims to treat multiple types of cancers. Nonetheless, Tyme Technologies Inc differentiates itself through its innovative approach and unique molecular platform.

Tyme Technologies Inc is primarily active in the pharmaceutical industry.

Tyme Technologies Inc. is a biotechnology company based in New York, USA. The business model of Tyme Technologies Inc. primarily focuses on the development and commercialization of innovative cancer therapies. The company concentrates on creating therapies that target cancer metabolism and harness the body's immune system response. Through extensive research and clinical trials, Tyme Technologies Inc. aims to provide patients with effective and personalized treatment options for various types of cancer. Their commitment to advancing cancer care and improving patient outcomes drives their business model. Tyme Technologies Inc. strives to revolutionize cancer treatment through their innovative therapies and dedication to scientific advancements.

Коефициентът на цена спрямо печалбата (КЦП) на Tyme Technologies е 0.

Коефициентът на цена към оборот (KUV) на Tyme Technologies е -0,00.

AlleAktien качественият резултат за Tyme Technologies е 2/10.

очаквана Tyme Technologies оборотът е -9160,81 Брд. USD.

Печалбата за Tyme Technologies в момента не може да бъде изчислена.

Tyme Technologies Inc. is a research-based biotechnology company that develops innovative cancer therapies. The company is headquartered in New York, USA and was founded in 2011. Tyme focuses on manufacturing drugs that aim to improve the current standard of cancer treatment. Tyme Technologies' business model is focused on the development, manufacturing, and marketing of new cancer drugs. The company operates active research and development programs to discover new cancer drugs for a variety of cancer types. It also has a range of already approved products. The company is divided into various divisions that are responsible for its business activities, including research and development, manufacturing, marketing, sales, and finance. Research and Development: Tyme Technologies heavily invests in research and development to develop new cancer drugs that provide patients with a better quality of life and survival chances. The company utilizes state-of-the-art scientific methods and technologies to understand the mechanisms of cancer cells and develop new therapies. Approved Products: Tyme Technologies has already brought a drug called "SM-88" to the market. It is an oral treatment for advanced, non-resectable, or metastatic solid tumors. SM-88 has the potential to be an effective addition to current cancer treatment. Manufacturing: Tyme Technologies has a modern production facility that enables the manufacturing of drugs based on Good Manufacturing Practices (GMP). The company emphasizes high quality standards and careful quality control to ensure that its drugs are safe and effective. Marketing and Sales: Tyme Technologies develops effective marketing and sales strategies to successfully position its products in the market. The company works closely with doctors and oncologists to ensure that its products meet the needs of patients and provide the best possible therapy. Finance: Tyme Technologies is committed to supporting its business activities through an effective financing structure. The company utilizes various financing options such as public offerings, venture capital, and strategic partnerships to finance its growth and expansion. In summary, Tyme Technologies is an innovative biotech company focused on the development of cancer drugs. The company heavily invests in research and development to discover new drugs for cancer treatment. Tyme Technologies is involved in manufacturing, marketing, and sales of drugs at various levels. It has also successfully brought an approved product to the market and continues to strive for sustainable growth.

Tyme Technologies разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Tyme Technologies в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Tyme Technologies е US90238J1034.

WKN на Tyme Technologies е A14XMS.

Тикерът на Tyme Technologies е TYME.

През последните 12 месеца Tyme Technologies изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Tyme Technologies да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Tyme Technologies в момента е .

Tyme Technologies изплаща дивидент на тримесечие. Той се разпределя в месеците .

Tyme Technologies платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Tyme Technologies се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Tyme Technologies на 30.12.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 30.12.2024 г..

Последното дивидентно плащане беше извършено на 30.12.2024 г..

През година 2023 Tyme Technologies изплати 0 USD под формата на дивиденти.

Дивидентите от Tyme Technologies се изплащат в USD.